Mirum’s ATEBRIOZ reduced abnormal bone volume in young children, but will the FDA expand its approval?
Mirum's ATEBRIOZ reduced abnormal bone volume in children aged 6 to under 12 with FOP. Can the results support FDA label expansion in 2027?
Pharma & Biotech